In the News
Improving health equity and diversity throughout the life sciences
Lloryn Hubbard discusses how life science companies can address the disparities within clinical trials and health equity.
The case for loosening trial eligibility reins
Dirk Reitsma notes that oncology studies have additional challenges compared to the many barriers to achieving diversity of populations in all clinical trials.
Cancer research and trends in cell therapy treatments
Jai Balkissoon and Evan Zynda highlight the key trends and challenges in cell and gene therapy, and explore the latest advancements in cell therapy for cancer treatment.
An intelligent drug development paradigm
Our experts describe an intelligent drug development paradigm that enables small pharma to implement a truth-seeking early development approach like those used by progressive big pharma companies.
Moving closer to dynamic drug development through automated solutions
Robert King explains that solutions are on the horizon that will help overcome the current bottlenecks and other challenges that are occurring in early drug development.
Health equity in pharma: communities most impacted by racial bias
Rose Blackburne discusses health equity and racial bias in pharma and how to address inequities in access and care.
CRO industry report
Our experts comment on the challenges, trends and focus of clinical research today.
CGT demands vision, partnership and patient-centricity to transform healthcare
Panteli Theocharous discusses the current landscape and future outlook for clinical research in cell and gene therapy, stressing the importance of partnerships with various stakeholders.
Measuring vaccine efficacy: the right endpoints are key to success
Endpoints are needed throughout the vaccine development life cycle. In this article, the authors discuss how to develop, assess and select endpoints at each development step.
